ADA 81st Symposium: Cardiovascular and Kidney Outcomes in Efpeglenatide
Jul 24, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Alan Martinez, PharmD Candidate, University of South Florida Taneja College of Pharmacy
With the introduction of this glucagon-like peptide-1 receptor agonist (GLP-1 RA), efpeglenatide, could we see new cardiovascular and renal benefits for patients with type 2 diabetes?
Patients with type 2 diabetes are at a higher risk of developing other complications if their HbA1c and glucose levels remain above goal. In addition, common comorbidities accompanying diabetes are cardiovascular and renal-based; this makes GLP-1 RAs a great option as they have shown to improve these outcomes in this patient population. Efpeglenatide is an exendin-4 (animal) based GLP-1 RA with a long half-life, thus administered subcutaneously once weekly. The purpose of the study is to assess the effectiveness of efpeglenatide in patients with type 2 diabetes concerning cardiovascular and kidney outcomes....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.